Loading...
•
Mar 31, 2024
Eton Q1 2024 Earnings Report
Eton Pharmaceuticals reported a 50% increase in revenue and a net loss reduction compared to the prior year period.
Key Takeaways
Eton Pharmaceuticals reported a strong start to 2024, marked by record product sales, a 50% revenue increase compared to Q1 2023, and the acquisition of PKU GOLIKE. The company also launched Nitisinone and submitted an NDA for ET-400.
Q1 2024 revenue reached $8.0 million, a 50% increase year-over-year.
The company achieved its 13th consecutive quarter of sequential product sales growth.
Eton acquired U.S. rights to PKU GOLIKE and launched Nitisinone, expanding its metabolic portfolio.
An NDA was submitted to the FDA for ET-400, with potential approval expected in early 2025.
Revenue by Segment
Forward Guidance
Eton Pharmaceuticals anticipates continued sequential quarter-over-quarter growth of product sales throughout 2024 and beyond. With the addition of PKU GOLIKE and Nitisinone, the company is positioned for a strong 2024 and gears up for potential launch of ET-400 in early 2025
Positive Outlook
- Continued sequential quarter-over-quarter growth of product sales is expected throughout 2024 and beyond.
- The company anticipates continued sales growth to result in positive operating cash flow throughout the remainder of 2024.
- Strong growth expected from existing products.
- The additions of PKU GOLIKE and Nitisinone will strenghten the portfolio.
- Potential launch of ET-400 in early 2025
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...